FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023967508> ?p ?o ?g. }

• W3023967508 endingPage "87" @default.
• W3023967508 startingPage "81" @default.
• W3023967508 abstract "The prostate-specific membrane antigen (PSMA) is an excellent target for theranostic applications in prostate cancer. However, PSMA-targeted radioligand therapy can cause undesirable effects due to high accumulation of PSMA radiotracers in salivary glands and kidneys. This study assessed orally administered monosodium glutamate (MSG) as a potential means of reducing kidney and salivary gland radiation exposure using a PSMA-targeting radiotracer. <b>Methods:</b> This prospective, double-blind, placebo-controlled study enrolled 10 patients with biochemically recurrent prostate cancer. Each subject served as his own control. PET/CT imaging sessions using 2-(3-{1-carboxy-5-[(6-¹⁸F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (¹⁸F-DCFPyL) were performed 3–7 d apart, after oral administration of either 12.7 g of MSG or placebo. Data from the 2 sets of images were analyzed by placing regions of interest on lacrimal, parotid, and submandibular glands; left ventricle; liver; spleen; kidneys; bowel; urinary bladder; gluteus muscle; and malignant lesions. The results from MSG and placebo scans were compared by paired analysis of the region-of-interest data. <b>Results:</b> In total, 142 pathologic lesions along with normal tissues were analyzed. As hypothesized a priori, there was a significant decrease in SUV_max corrected for lean body mass (SUL_max) on images obtained after MSG administration in the parotids (24% ± 14%, <i>P</i> = 0.001), submandibular glands (35% ± 11%, <i>P</i> < 0.001), and kidneys (23% ± 26%, <i>P</i> = 0.014). Significant decreases were also observed in the lacrimal glands (49% ± 13%, <i>P</i> < 0.001), liver (15% ± 6%, <i>P</i> < 0.001), spleen (28% ± 13%, <i>P</i> = 0.001), and bowel (44% ± 13%, <i>P</i> < 0.001). A mildly lower blood pool SUL_mean was observed after MSG administration (decrease of 11% ± 13%, <i>P</i> = 0.021). However, significantly lower radiotracer uptake in terms of SUL_mean, SUL_peak, and SUL_max was observed in malignant lesions on scans performed after MSG administration than on the placebo studies (SUL_max median decrease, 33%; range, −1% to 75%; <i>P</i> < 0.001). No significant adverse events occurred after placebo or MSG administration, and vital signs were stable. <b>Conclusion:</b> Orally administered MSG significantly decreased salivary gland, kidney, and other normal-organ PSMA radiotracer uptake in human subjects, using ¹⁸F-DCFPyL as an exemplar. However, MSG caused a corresponding reduction in tumor uptake, which may limit the benefits of this approach for diagnostic and therapeutic applications." @default.
• W3023967508 created "2020-05-13" @default.
• W3023967508 creator A5004614891 @default.
• W3023967508 creator A5035333633 @default.
• W3023967508 creator A5040772609 @default.
• W3023967508 creator A5055231983 @default.
• W3023967508 creator A5060184273 @default.
• W3023967508 creator A5080246393 @default.
• W3023967508 date "2020-05-08" @default.
• W3023967508 modified "2023-10-17" @default.
• W3023967508 title "The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study" @default.
• W3023967508 cites W1992868992 @default.
• W3023967508 cites W2033261019 @default.
• W3023967508 cites W2069422722 @default.
• W3023967508 cites W2103959341 @default.
• W3023967508 cites W2110065044 @default.
• W3023967508 cites W2110534364 @default.
• W3023967508 cites W2123526148 @default.
• W3023967508 cites W2141454098 @default.
• W3023967508 cites W2143030220 @default.
• W3023967508 cites W2160881737 @default.
• W3023967508 cites W2166918329 @default.
• W3023967508 cites W2170794639 @default.
• W3023967508 cites W2287868019 @default.
• W3023967508 cites W2288818676 @default.
• W3023967508 cites W2343936933 @default.
• W3023967508 cites W2345590823 @default.
• W3023967508 cites W2513308461 @default.
• W3023967508 cites W2525349940 @default.
• W3023967508 cites W2532226140 @default.
• W3023967508 cites W2606187374 @default.
• W3023967508 cites W2743828160 @default.
• W3023967508 cites W2752389930 @default.
• W3023967508 cites W2771847508 @default.
• W3023967508 cites W2780781461 @default.
• W3023967508 cites W2782678772 @default.
• W3023967508 cites W2784080506 @default.
• W3023967508 cites W2793895106 @default.
• W3023967508 cites W2799931007 @default.
• W3023967508 cites W2885727665 @default.
• W3023967508 cites W2889014405 @default.
• W3023967508 cites W2911188335 @default.
• W3023967508 cites W2911299254 @default.
• W3023967508 cites W2938206213 @default.
• W3023967508 cites W2942632852 @default.
• W3023967508 cites W3008309348 @default.
• W3023967508 doi "https://doi.org/10.2967/jnumed.120.246983" @default.
• W3023967508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32385167" @default.
• W3023967508 hasPublicationYear "2020" @default.
• W3023967508 type Work @default.
• W3023967508 sameAs 3023967508 @default.
• W3023967508 citedByCount "24" @default.
• W3023967508 countsByYear W30239675082020 @default.
• W3023967508 countsByYear W30239675082021 @default.
• W3023967508 countsByYear W30239675082022 @default.
• W3023967508 countsByYear W30239675082023 @default.
• W3023967508 crossrefType "journal-article" @default.
• W3023967508 hasAuthorship W3023967508A5004614891 @default.
• W3023967508 hasAuthorship W3023967508A5035333633 @default.
• W3023967508 hasAuthorship W3023967508A5040772609 @default.
• W3023967508 hasAuthorship W3023967508A5055231983 @default.
• W3023967508 hasAuthorship W3023967508A5060184273 @default.
• W3023967508 hasAuthorship W3023967508A5080246393 @default.
• W3023967508 hasBestOaLocation W30239675081 @default.
• W3023967508 hasConcept C121608353 @default.
• W3023967508 hasConcept C126322002 @default.
• W3023967508 hasConcept C126894567 @default.
• W3023967508 hasConcept C142724271 @default.
• W3023967508 hasConcept C20417620 @default.
• W3023967508 hasConcept C204787440 @default.
• W3023967508 hasConcept C27081682 @default.
• W3023967508 hasConcept C2776235491 @default.
• W3023967508 hasConcept C2780091579 @default.
• W3023967508 hasConcept C2780192828 @default.
• W3023967508 hasConcept C2989005 @default.
• W3023967508 hasConcept C71924100 @default.
• W3023967508 hasConceptScore W3023967508C121608353 @default.
• W3023967508 hasConceptScore W3023967508C126322002 @default.
• W3023967508 hasConceptScore W3023967508C126894567 @default.
• W3023967508 hasConceptScore W3023967508C142724271 @default.
• W3023967508 hasConceptScore W3023967508C20417620 @default.
• W3023967508 hasConceptScore W3023967508C204787440 @default.
• W3023967508 hasConceptScore W3023967508C27081682 @default.
• W3023967508 hasConceptScore W3023967508C2776235491 @default.
• W3023967508 hasConceptScore W3023967508C2780091579 @default.
• W3023967508 hasConceptScore W3023967508C2780192828 @default.
• W3023967508 hasConceptScore W3023967508C2989005 @default.
• W3023967508 hasConceptScore W3023967508C71924100 @default.
• W3023967508 hasIssue "1" @default.
• W3023967508 hasLocation W30239675081 @default.
• W3023967508 hasOpenAccess W3023967508 @default.
• W3023967508 hasPrimaryLocation W30239675081 @default.
• W3023967508 hasRelatedWork W1544952821 @default.
• W3023967508 hasRelatedWork W1977334426 @default.
• W3023967508 hasRelatedWork W1980188241 @default.
• W3023967508 hasRelatedWork W1980245127 @default.
• W3023967508 hasRelatedWork W2036910832 @default.
• W3023967508 hasRelatedWork W2106003470 @default.

• next